IntrinsicIntrinsic
← All summaries

Alector, Inc.

ALEC
Financials & Chart →

Business Summary

Alector, Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases, addressing areas of high unmet medical need. The company's strategy is informed by advances in disease biology, including misfolded or deficient proteins, lysosomal dysfunction, and immune and neuronal pathway disruption. Alector aims to develop product candidates that remove pathogenic proteins, replace deficient proteins, and restore normal cellular function. A key component of its strategy is the Alector Brain Carrier (ABC) platform, a proprietary blood-brain barrier (BBB) delivery technology designed to improve central nervous system exposure across multiple therapeutic modalities . The company also invests in biomarkers and biomarker assays to guide patient selection, demonstrate target and pathway engagement, and assess biological impact in the clinic .

Alector's core business model involves generating revenue primarily through collaboration arrangements, as it has no products approved for commercial sale and has not generated any revenue from product sales to date . The company recognizes revenue from upfront payments and milestone payments from collaborators, such as GSK, over time as research and development services are provided, or at a point in time for development licenses . The company's primary customer segments are its collaboration partners, with the GSK Agreement being a significant source of current and expected future revenue .

The company's portfolio includes nivisnebart (formerly AL101/GSK4527226), an investigational progranulin (PGRN)-elevating antibody. This candidate has completed enrollment in a placebo-controlled, double-blinded Phase 2 study in early Alzheimer’s disease (AD) under a July 2021 Collaboration and License Agreement with Glaxo Wellcome UK Limited (GSK Agreement) . Nivisnebart is designed to elevate PGRN levels in the brain by blocking and downregulating the sortilin (SORT1) receptor, which degrades PGRN . The PROGRESS-AD Phase 2 trial, which enrolled approximately 282 patients, is designed to assess the safety and efficacy of two dose levels of nivisnebart compared to placebo, with trial completion expected in 2026 and an independent interim futility analysis planned for the first half of 2026 . In August 2025, the first patient from PROGRESS-AD was enrolled and dosed in the optional open-label extension (OLE) study, which is ongoing . Under the GSK Agreement, Alector is responsible for funding up to $140.5 million for the conduct of this initial Phase 2 trial .

Alector also has wholly-owned programs in preclinical development, leveraging its Alector Brain Carrier (ABC) platform. These include AL137, a brain-penetrant anti-amyloid beta antibody for AD, designed to remove brain Aβ plaques with potential for minimal amyloid-related imaging abnormalities (ARIA) and subcutaneous delivery . AL137 features a high-affinity, fully human antibody that selectively binds PyroGlu3 and a fully active effector function, combined with Alector’s proprietary ABC . Preclinical studies have shown robust brain penetration in non-human primates and amyloid beta 42 reduction in murine studies with an AL137 surrogate . The company targets submission of an Investigational New Drug (IND) application for AL137 in the fourth quarter of 2026 or the first quarter of 2027 .

Another wholly-owned program is AL050, a GCase enzyme replacement therapy paired with ABC technology, in preclinical development for Parkinson’s disease (PD) and Lewy body dementia (LBD) in patients with GBA1 gene mutations . AL050 features an engineered GCase with improved activity and stability, a silenced effector function, and ABC designed to enhance BBB delivery . Preclinical studies demonstrated AL050 doubled GCase activity in rodents and non-human primates and reduced toxic substrate accumulation in a rodent GBA disease model . An IND application for AL050 is targeted for 2027 .

The company is also advancing an ABC-enabled siRNA platform, with AL064 as its lead siRNA program, targeting tau for AD and other tauopathies . AL064 aims to prevent tau mRNA and protein synthesis to remove toxic tau and slow cognitive decline . Other early-stage siRNA programs include ADP062-ABC, an alpha-synuclein siRNA for PD, and ADP065-ABC, an NLRP3 siRNA for multiple neurodegenerative conditions . AL064 is advancing to IND-enabling studies .

For the fiscal year ended December 31, 2025, Alector reported collaboration revenue of $21.0 million , a significant decrease from $100.6 million in 2024 . The gross profit is not explicitly stated, but the company reported a net loss of $142.9 million for 2025, compared to a net loss of $119.0 million in 2024 . Operating expenses totaled $177.1 million in 2025 , down from $245.6 million in 2024 . Research and development expenses were $123.1 million in 2025 , a decrease from $185.9 million in 2024 . General and administrative expenses were $54.0 million in 2025 , down from $59.6 million in 2024 . Loss from operations was $156.0 million in 2025 , compared to $145.0 million in 2024 . Other income, net, was $13.2 million in 2025 , a decrease from $26.1 million in 2024 . Basic and diluted net loss per share was $(1.39) in 2025 , compared to $(1.23) in 2024 . As of December 31, 2025, cash and cash equivalents were $65.8 million , marketable securities were $190.2 million , and total current assets were $266.5 million . Total liabilities were $262.6 million , and total stockholders' equity was $30.6 million . The company had an accumulated deficit of $972.1 million as of December 31, 2025 .

The year-over-year comparison shows a substantial decrease in collaboration revenue by $79.6 million , primarily due to the satisfaction of performance obligations for the AL002 program and the latozinemab FTD-C9orf72 Phase 2 trial in the fourth quarter of 2024 . Research and development expenses decreased by $62.8 million , mainly attributable to the reduction in expenses for the AL002 program and a decrease in personnel-related costs due to workforce reductions . General and administrative expenses also decreased by $5.6 million due to lower personnel-related costs from reductions in force . Other income, net, decreased by $12.9 million due to lower interest income from a reduction in marketable securities used to fund operations . The net loss increased by $23.9 million from 2024 to 2025.

Significant operational developments during the period include the completion of enrollment in the PROGRESS-AD Phase 2 study for nivisnebart in April 2025 , and the enrollment and dosing of the first patient in the optional open-label extension study in August 2025 . The company initiated a reduction in force in October 2025, impacting approximately 47% of its workforce, to align resources with strategic priorities following the results of the Phase 3 INFRONT-3 clinical trial for latozinemab, which failed to meet its primary endpoint . This decision led to the discontinuation of the open label extension and continuation study for latozinemab . Additionally, the AL002 program was terminated in November 2024 after its INVOKE-2 Phase 2 clinical trial failed to meet the primary endpoint . The company also approved a plan in August 2024 to transition operations from its Newark, California facility to its South San Francisco headquarters, with the intention to sublease the Newark facility .

Business Outlook

Alector anticipates continuing to incur net losses for the foreseeable future, as it does not expect to generate revenue from product sales for several years, if at all . The company's revenue for the next several years is expected to be derived primarily from the GSK Agreement . As of December 31, 2025, Alector had cash, cash equivalents, and marketable securities of $256.0 million, which is anticipated to provide a runway at least through 2027 . This estimate is based on assumptions that may prove inaccurate, and the company could utilize its available capital resources sooner than expected . Alector may also seek additional financing opportunistically through public equity or debt financings, license agreements, collaborative agreements, asset sales, or other sources .

A major growth area for Alector is the advancement of its wholly-owned preclinical programs, particularly those leveraging the Alector Brain Carrier (ABC) platform. The company is targeting the submission of an Investigational New Drug (IND) application for AL137, its brain-penetrant anti-amyloid beta antibody for Alzheimer’s disease, in the fourth quarter of 2026 or the first quarter of 2027, contingent on the timing of GMP clinical supply production . AL137 is designed to remove brain Aβ plaques with the potential for minimal amyloid-related imaging abnormalities (ARIA) and subcutaneous delivery . Another significant growth area is the AL050 program, a GCase enzyme replacement therapy paired with ABC technology for Parkinson’s disease and Lewy body dementia . Alector is targeting the submission of an IND application for AL050 in 2027 . These programs represent the company's strategic focus on developing genetically validated therapies that remove pathogenic proteins, replace deficient proteins, and restore normal cellular function .

The company is also advancing its ABC-enabled siRNA platform, with AL064, a tau siRNA for AD and other tauopathies, as its lead program, which is progressing to IND-enabling studies . Additional early-stage siRNA programs, ADP062-ABC for alpha-synuclein in PD and ADP065-ABC for NLRP3 in multiple neurodegenerative conditions, are moving toward lead candidate selection . Alector continues to evolve its research and development plans and timing for these ABC-enabled siRNA programs . The ABC platform is designed to enable targeted, non-invasive peripheral administration of therapeutics to the brain, aiming for broad and homogeneous brain distribution, elimination of intrathecal delivery, and lower doses to potentially widen therapeutic windows and facilitate convenient delivery options like subcutaneous dosing .

Operationally, Alector expects its research and development expenses related to latozinemab and AL002 to decrease in the foreseeable future due to the discontinuation and wind-down of their respective clinical trials . However, the company will continue to invest in research and development activities for its research and preclinical pipeline and the advancement of these programs into clinical trials . The company initiated a reduction in force in October 2025, impacting approximately 47% of its workforce, to align resources with strategic priorities . Total incremental restructuring charges associated with this reduction are approximately $7.3 million, primarily for severance and related termination benefits, with cash payments expected in the first half of 2026 .

Regarding capital allocation, Alector has an omnibus shelf registration statement on Form S-3 with the SEC, effective May 1, 2023, permitting the issuance of up to $400 million in common stock, other equity securities, and/or debt securities . As of December 31, 2025, the company had issued 7,110,162 shares and received approximately $20.0 million in net proceeds from sales of securities under an at-the-market sales agreement with TD Securities . In January 2024, Alector sold 10,869,566 shares of common stock at $6.57 per share in a public offering, generating aggregate net proceeds of $71.1 million . Additionally, on November 14, 2024, Alector entered into a loan agreement for up to $50.0 million in term loans, with an initial $25.0 million tranche available through June 30, 2026, of which $10.0 million was borrowed at closing . The second tranche of $25.0 million is available at the sole discretion of the Lenders .

Management has explicitly flagged several structural headwinds and execution risks. The company has a limited operating history and no products approved for commercial sale, making future success and viability difficult to evaluate . Drug development is a highly uncertain undertaking, with prior terminations of four product candidates, including latozinemab and AL002, due to failure to meet primary endpoints . Alector will need substantial additional financing to complete development and commercialization, and failure to obtain this capital could force delays or termination of efforts . The company must prioritize development of certain product candidates due to significant resource requirements, risking expenditure on unsuccessful programs or missing more profitable opportunities . Clinical trials may encounter substantial delays or fail to demonstrate safety and efficacy, preventing or limiting regulatory approval . The company faces significant competition, with some competitors having greater financial resources and expertise, and some pursuing the same targets or developing competing blood-brain barrier transport technologies . The manufacture of product candidates is complex, and difficulties in production or failure to meet regulatory standards could delay supply or impact cost structure . If Alector cannot establish sales and marketing capabilities or secure third-party agreements, commercialization may not be successful . Products, if approved, may fail to achieve market acceptance by physicians, patients, and payors . Unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives could harm the business . The company's product candidates may face biosimilar competition sooner than anticipated, potentially reducing market exclusivity .

Risk Factors

Alector faces material risks across several domains. Macroeconomic conditions, including global recessions, increased inflation, supply chain disruptions, trade tariffs, and geopolitical events such as the ongoing conflicts in Russia-Ukraine and the Middle East, could adversely impact operations, financial results, and stock price . The company is highly dependent on its key personnel, and failure to attract and retain qualified individuals, especially after workforce reductions, could hinder business strategy implementation . The biotechnology and pharmaceutical industries are highly competitive, with large companies like Biogen, Eli Lilly, Merck, Roche, and Eisai pursuing similar indications and targets, and some developing competing blood-brain barrier transport technologies, including those acting through the transferrin receptor (TfR) . Regulatory approval processes are lengthy, time-consuming, and unpredictable, with potential for delays due to changes in FDA policies, budget reductions, or increased litigation challenging agency decisions . Product candidates may cause undesirable side effects, such as the ARIA observed in the INVOKE-2 trial, which could halt clinical development, prevent regulatory approval, or limit commercial potential . The company relies heavily on third-party collaborators and contract development and manufacturing organizations (CDMOs), and their unsatisfactory performance, termination of agreements, or inability to comply with regulatory standards could delay or impair development and commercialization efforts . Intellectual property protection is uncertain, with risks that patents may not issue, be sufficiently broad, or be challenged, invalidated, or circumvented by competitors, potentially leading to substantial litigation costs and diversion of resources . Furthermore, the company's Loan Agreement contains covenants that limit operating and financial flexibility, and a breach could result in an event of default and acceleration of outstanding loans .

Management Priorities

Management's overall tone emphasizes a strategic pivot towards genetically validated therapies and the proprietary Alector Brain Carrier (ABC) platform, following recent clinical trial setbacks. The company acknowledges its history of net losses and the substantial financial resources required for drug development, stating that its existing cash, cash equivalents, and marketable securities of $256.0 million are anticipated to provide a runway at least through 2027 . This estimate is based on assumptions that may prove inaccurate, and additional financing may be sought opportunistically . A key strategic priority is the advancement of the preclinical and research pipeline, particularly ABC-enabled product candidates like AL137 for Alzheimer's disease, targeting an IND submission in Q4 2026 or Q1 2027 , and AL050 for Parkinson's disease and Lewy body dementia, targeting an IND submission in 2027 . Another strategic priority is the continued evolution of ABC-enabled siRNA programs, including AL064 for tauopathies, which is advancing to IND-enabling studies . Management also highlights the importance of effectively managing the organization, as evidenced by the reduction in force in October 2025, impacting approximately 47% of the workforce, to align resources with strategic priorities .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 1, Business — Overview
  3. [3] Item 7, MD&A — Overview
  4. [4] Item 7, MD&A — Revenue
  5. [5] Item 7, MD&A — Revenue
  6. [6] Item 1, Business — Overview
  7. [7] Item 1, Business — Nivisnebart for the Treatment of Alzheimer’s Disease and Parkinson’s Disease
  8. [8] Item 1, Business — Nivisnebart for the Treatment of Alzheimer’s Disease and Parkinson’s Disease
  9. [9] Item 1, Business — Nivisnebart for the Treatment of Alzheimer’s Disease and Parkinson’s Disease
  10. [10] Item 1, Business — Strategic Alliance with GSK
  11. [11] Item 1, Business — AL137 Program
  12. [12] Item 1, Business — AL137 Program
  13. [13] Item 1, Business — AL137 Program
  14. [14] Item 1, Business — AL137 Program
  15. [15] Item 1, Business — AL050 Program
  16. [16] Item 1, Business — AL050 Program
  17. [17] Item 1, Business — AL050 Program
  18. [18] Item 1, Business — AL050 Program
  19. [19] Item 1, Business — ABC-Enabled siRNA Platform
  20. [20] Item 1, Business — ABC-Enabled siRNA Platform
  21. [21] Item 1, Business — ABC-Enabled siRNA Platform
  22. [22] Item 1, Business — ABC-Enabled siRNA Platform
  23. [23] Item 7, MD&A — Results of Operations
  24. [24] Item 7, MD&A — Results of Operations
  25. [25] Item 7, MD&A — Results of Operations
  26. [26] Item 7, MD&A — Results of Operations
  27. [27] Item 7, MD&A — Results of Operations
  28. [28] Item 7, MD&A — Results of Operations
  29. [29] Item 7, MD&A — Results of Operations
  30. [30] Item 7, MD&A — Results of Operations
  31. [31] Item 7, MD&A — Results of Operations
  32. [32] Item 7, MD&A — Results of Operations
  33. [33] Item 7, MD&A — Results of Operations
  34. [34] Item 7, MD&A — Results of Operations
  35. [35] Item 7, MD&A — Results of Operations
  36. [36] Item 7, MD&A — Results of Operations
  37. [37] Item 7, MD&A — Results of Operations
  38. [38] Item 7, MD&A — Results of Operations
  39. [39] Item 7, MD&A — Liquidity and Capital Resources
  40. [40] Item 7, MD&A — Liquidity and Capital Resources
  41. [41] Item 8, Consolidated Balance Sheets
  42. [42] Item 8, Consolidated Balance Sheets
  43. [43] Item 8, Consolidated Balance Sheets
  44. [44] Item 7, MD&A — Overview
  45. [45] Item 7, MD&A — Revenue
  46. [46] Item 7, MD&A — Revenue
  47. [47] Item 7, MD&A — Research and Development Expenses
  48. [48] Item 7, MD&A — Research and Development Expenses
  49. [49] Item 7, MD&A — General and Administrative Expenses
  50. [50] Item 7, MD&A — General and Administrative Expenses
  51. [51] Item 7, MD&A — Other Income, Net
  52. [52] Item 7, MD&A — Other Income, Net
  53. [53] Item 7, MD&A — Results of Operations
  54. [54] Item 1, Business — Nivisnebart for the Treatment of Alzheimer’s Disease and Parkinson’s Disease
  55. [55] Item 1, Business — Nivisnebart for the Treatment of Alzheimer’s Disease and Parkinson’s Disease
  56. [56] Item 7, MD&A — Overview
  57. [57] Item 1A, Risk Factors — Drug development is a highly uncertain undertaking and involves a substantial degree of risk.
  58. [58] Item 1A, Risk Factors — Drug development is a highly uncertain undertaking and involves a substantial degree of risk.
  59. [59] Item 2, Properties
  60. [60] Item 7, MD&A — Overview
  61. [61] Item 7, MD&A — Revenue
  62. [62] Item 7, MD&A — Liquidity and Capital Resources
  63. [63] Item 7, MD&A — Future Funding Requirements
  64. [64] Item 7, MD&A — Future Funding Requirements
  65. [65] Item 1, Business — AL137 Program
  66. [66] Item 1, Business — AL137 Program
  67. [67] Item 1, Business — AL050 Program
  68. [68] Item 1, Business — AL050 Program
  69. [69] Item 1, Business — Our Strategy
  70. [70] Item 1, Business — ABC-Enabled siRNA Platform
  71. [71] Item 1, Business — ABC-Enabled siRNA Platform
  72. [72] Item 1, Business — ABC-Enabled siRNA Platform
  73. [73] Item 1, Business — Alector Brain Carrier (ABC), Our Proprietary and Versatile Blood-Brain Barrier Technology Platform
  74. [74] Item 7, MD&A — Research and Development Expenses
  75. [75] Item 7, MD&A — Research and Development Expenses
  76. [76] Item 7, MD&A — Overview
  77. [77] Item 1A, Risk Factors — We will need to effectively manage the size and capabilities of our organization.
  78. [78] Item 7, MD&A — Future Funding Requirements
  79. [79] Item 7, MD&A — Future Funding Requirements
  80. [80] Item 7, MD&A — Future Funding Requirements
  81. [81] Item 7, MD&A — Future Funding Requirements
  82. [82] Item 7, MD&A — Future Funding Requirements
  83. [83] Item 1A, Risk Factors — We are in various stages of drug development and have a limited operating history and no products approved for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability.
  84. [84] Item 1A, Risk Factors — Drug development is a highly uncertain undertaking and involves a substantial degree of risk.
  85. [85] Item 1A, Risk Factors — We will need to obtain substantial additional financing to complete the development and any commercialization of our product candidates, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce, or terminate our commercialization efforts, product development, or other operations.
  86. [86] Item 1A, Risk Factors — Due to the significant resources required for the development of our product candidates, and depending on our ability to access capital, we must prioritize development of certain product candidates.
  87. [87] Item 1A, Risk Factors — We may encounter substantial delays in our clinical trials or may not be able to conduct or complete our clinical trials on the timelines we expect, if at all.
  88. [88] Item 1A, Risk Factors — We face significant competition in an environment of rapid technological and scientific change.
  89. [89] Item 1A, Risk Factors — The manufacture of our product candidates is complex, and we may encounter difficulties in production.
  90. [90] Item 1A, Risk Factors — If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any product candidates we may develop, we may not be successful in commercializing those product candidates if and when they are approved.
  91. [91] Item 1A, Risk Factors — Even if any product candidates we develop receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors, and others in the medical community necessary for commercial success.
  92. [92] Item 1A, Risk Factors — Any products we or a collaboration partner commercialize may become subject to unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives, which would harm our business.
  93. [93] Item 1A, Risk Factors — Our product candidates for which we intend to seek approval may face biosimilar competition sooner than anticipated.
  94. [94] Item 1A, Risk Factors — Our operations, financial results, and the market price of our common stock could be adversely impacted by the effects of worldwide economic conditions, including macroeconomic downturns, global recessions, increased inflation, supply chain disruptions, trade tariffs or other disruptions in global trade, pandemics or other public health outbreaks, and geopolitical events and conflicts.
  95. [95] Item 1A, Risk Factors — We are highly dependent on our key personnel, and if we are not successful in attracting, motivating, and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.
  96. [96] Item 1A, Risk Factors — We face significant competition in an environment of rapid technological and scientific change.
  97. [97] Item 1A, Risk Factors — The regulatory approval processes of the FDA, EMA, and comparable foreign regulatory authorities are lengthy, time consuming, and inherently unpredictable.
  98. [98] Item 1A, Risk Factors — Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences.
  99. [99] Item 1A, Risk Factors — We expect to depend on collaborations with third parties for the research, development, and commercialization of certain of the product candidates we may develop.
  100. [100] Item 1A, Risk Factors — If we are unable to obtain and maintain patent protection for any product candidates we develop, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop may be adversely affected.
  101. [101] Item 1A, Risk Factors — Our Loan Agreement requires us to comply with specified operating covenants and places restrictions on our operating and financial flexibility.
  102. [102] Item 7, MD&A — Liquidity and Capital Resources
  103. [103] Item 7, MD&A — Liquidity and Capital Resources
  104. [104] Item 7, MD&A — Future Funding Requirements
  105. [105] Item 1, Business — AL137 Program
  106. [106] Item 1, Business — AL050 Program
  107. [107] Item 1, Business — ABC-Enabled siRNA Platform
  108. [108] Item 7, MD&A — Overview

Analysis on 5/19/2026